Anales de la RANM

215 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRASPLANTE DE HÍGADO An RANM. 2026;143(02): 207 - 215 Jiménez Romero C, et al. 40. Mithoefer AB, Supran S, Freeman RB. Risk fac- tors associated with the development of skin cancer after liver transplantation. Liver Trans- pl 2002;8:939-944. 41. Vallejo GH, Romero CJ, de Vicente JC. In- cidence and risk factors for cancer after li- ver transplantation. Crit Rev Oncol Hematol 2005;56:87-99. 42. Watt KD, Pedersen RA, Kremers WK, Heim- bach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from the novo malignancy after liver transplantation. Gas- troenterology 2009;137:2010-2017. 43. Carenco C, Faure S, Herrero A, Assenat E, Duny Y, Danan G, et al. Incidence of solid or- gan cancers after liver transplantation: compa- rison with regional cancer incidences rates and risk factors. Liver Int 2015;35:1748-1755. 44. Leithead JA, Ferguson JW, Hayes PC. Smoking- related morbidity and mortality following liver transplantation. Liver Transpl 2008;14:1159- 1164. 45. Patel JA, Daoud D, Jain A. Review of standar- dized incidence ratios (SIR) of non-lymphoid de novo malignancies after liver transplanta- tion: structures analysis of global differences. Transplant Rev 2022;36:100670. 46. Jiménez C, Manrique A, Marqués E, et al. Inci- dence and risk factors for the development of lung tumors after liver transplantation. Trans- pl Int 2007;20:57-63. 47. Palaniyappan N, Peach E, Pearce F, et al. Long- term outcomes (beyond 5 years) of liver trans- plant recipients – A transatlantic multicenter study. Liver Transpl 2024;30:170-181. 48. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal or- gan. N Engl J Med 2003;349:931-940. 49. Saliba F, Duvoux C, Guhenheim J, et al. Effica- cy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after li- ver transplantation: a multicenter randomized trial. Am J Transpl 2017;17:1843-1852. 50. Jiménez-Romero C, Justo Alonso I, Caso Maestro O, et al. Indications and long-term outcomes of using mycophenolate mofetil mo- notherapy in substitution for calcineurin in- hibitors in liver transplantation. Transpl Int 2025;38:13790. Si desea citar nuestro artículo: Jiménez Romero C, Moreno González E, Caso Maestro O, Marcacuzco Quinto A, Justo Alonso I. Resultados del trasplante hepático en pa- cientes adultos con más de veinte años de seguimiento. An RANM. 2026;143(02): 207– 215. DOI: 10.32440/ar.2026.143.02.r ev06